Pipelines

합성 신약 진행 프로젝트 테이블
Indication		Research	Preclinical	Phase I	Phase II	Phase III
CKD-943** - Opioid Receptor Kappa agonist - No CNS related adverse events (affects PNS only)	Pain, Uremic pruritus
CKD-516 - Tublin Polymerization inhibitor (Vascular disrupting agent)	Colorectal cancer
CKD-581 - Pan-HDAC inhibitor	Multiple myeloma
CKD-506 - HDAC6 inhibitor	Autoimmune disease
CKD-504 - HDAC6 inhibitor	Huntington’s disease
CKD-508 - CETP inhibitor	Dyslipidemia
CKD-510 - HDAC6 inhibitor	Rare disease

CKD-943** : License-in from Cara Therapeutics in the US

바이오 의약품 진행 프로젝트 테이블
Indication		Research	Preclinical	Phase I	Phase II	Phase III
CKD-11101 - NESP/ARANESP Biosimilar (2nd generation of EPO)	Anemia(Abroad)
CKD-701 - Lucentis Biosimilar	AMD
CKD-702 - Bispecific antibody	Cancer
CKD-971* - IFN-alpha kinoid CKD-971*: License-in from Neovacs in France	Lupus

개량신약 진행 프로젝트 테이블
Indication		Research	Preclinical	Phase I	Phase II	Phase III
CKD-398	Diabetes
CKD-391	Dyslipidemia
CKD-386	Dyslipidemia/Hypertension
CKD-841 - Sustained release injection	Cancer
CKD-396	Diabetes
CKD-333	Dyslipidemia/Hypertension
CKD-351	Glaucoma
CKD-491	Periodontitis
CKD-497	Bronchitis
CKD-495	Gastritis
CKD-385	Hypertension/Heart failure/Angina pectoris